Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EPOGEN/PROCRIT vs RETACRIT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Erythropoiesis-stimulating agent that binds to and activates the erythropoietin receptor on erythroid progenitor cells, stimulating proliferation and differentiation into mature red blood cells.
RETACRIT (epoetin alfa-epbx) is a recombinant human erythropoietin that stimulates erythropoiesis by binding to and activating the erythropoietin receptor on erythroid progenitor cells, promoting their survival, proliferation, and differentiation into mature red blood cells.
Treatment of anemia due to chronic kidney disease (CKD) in patients on dialysis and not on dialysis,Treatment of anemia due to zidovudine in HIV-infected patients,Treatment of anemia due to myelosuppressive chemotherapy in patients with non-myeloid malignancies,Reduction of allogeneic red blood cell transfusions in patients undergoing elective, noncardiac, nonvascular surgery
Treatment of anemia due to chronic kidney disease (CKD) in patients on dialysis and not on dialysis,Treatment of anemia in HIV-infected patients treated with zidovudine,Treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy,Reduction of allogeneic red blood cell transfusions in patients undergoing elective, noncardiac, nonvascular surgery
50-100 units/kg intravenously or subcutaneously three times weekly. Initial dose 50 units/kg three times weekly; adjust to maintain hemoglobin target (usually 10-12 g/d L).
50-100 IU/kg intravenously or subcutaneously three times weekly; initial dose 50 IU/kg three times weekly, titrated to target hemoglobin 10-12 g/d L.
Terminal half-life: ~4-13 hours in healthy subjects; prolonged to 13-28 hours in chronic kidney disease or on dialysis (due to reduced clearance).
Terminal elimination half-life is ~2.5-4.5 hours following intravenous administration; shorter in children; prolonged in hepatic impairment.
Metabolized by proteolytic degradation into small peptides and amino acids; not metabolized by CYP450 enzymes.
Epoetin alfa-epbx is a protein; metabolism is expected to involve proteolytic degradation via catabolic pathways, similar to endogenous erythropoietin. No specific metabolic enzymes have been identified; clearance is primarily through receptor-mediated uptake and proteolysis.
Primarily hepatic metabolism; ~10% excreted unchanged in urine. Fecal elimination negligible.
Primarily hepatic metabolism; ~10% excreted unchanged in urine, remainder via feces as metabolites.
Approximately 50% bound to serum proteins; no specific binding protein identified.
Primarily binds to transferrin; iron is 100% bound to transferrin after dissociation from complex.
Vd = 0.03–0.06 L/kg, approximating plasma volume; indicates limited extravascular distribution.
Vd is approximately 0.067-0.22 L/kg; reflects distribution into plasma and extracellular fluid; limited tissue penetration initially.
Subcutaneous: ~20-30% compared to IV.
Not orally bioavailable; administered intravenously (100% bioavailability for IV route).
No standard GFR-based adjustment for epoetin alfa; dosing is based on hemoglobin response. In chronic kidney disease, initiate when hemoglobin <10 g/d L; titrate to avoid hemoglobin >11 g/d L.
For CKD patients, epoetin alfa dosing is independent of GFR; adjust based on hemoglobin response. No specific GFR-based dose adjustments, but start at 50-100 IU/kg three times weekly for dialysis patients.
No specific Child-Pugh based adjustments. Use with caution in severe hepatic impairment; monitor hemoglobin closely.
No specific Child-Pugh based adjustments. Use with caution in severe hepatic impairment; monitor for adverse effects.
Children: 50 units/kg intravenously or subcutaneously three times weekly; adjust by 25 units/kg increments based on hemoglobin response. For anemia in chronic kidney disease: initial 50 units/kg three times weekly.
0.5-50 IU/kg subcutaneously or intravenously three times weekly, titrated to target hemoglobin. For pediatric CKD, initial dose 50 IU/kg three times weekly.
No specific dose adjustment in elderly; use same dosing principles as adults. Monitor for cardiovascular events and thromboembolism due to higher baseline risk.
No specific dose adjustment; initiate at lower end of dosing range (50 IU/kg three times weekly) and titrate slowly, monitoring for hypertension and thrombotic events.
Increased risk of serious cardiovascular events, myocardial infarction, stroke, venous thromboembolism, vascular access thrombosis, and tumor progression or recurrence when targeting hemoglobin levels >11 g/d L. Use the lowest dose to avoid red blood cell transfusion. Not indicated for use in patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure.
WARNING: INCREASED RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE. Chronic Kidney Disease: In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target a hemoglobin level of 13 g/d L or greater. No trial has identified a hemoglobin target level, ESA dose, or dosing strategy that does not increase these risks. Use the lowest dose sufficient to reduce the need for red blood cell transfusions. Cancer: ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in clinical studies of patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers. To decrease these risks, as well as the risk of serious cardiovascular and thromboembolic reactions, use the lowest dose needed to avoid red blood cell transfusions. Use ESAs only for anemia from myelosuppressive chemotherapy. ESAs are not indicated for patients receiving myelosuppressive chemotherapy when the anticipated outcome is cure. Discontinue following the completion of a chemotherapy course. Perisurgery: Due to increased risk of deep venous thrombosis (DVT), use prophylactic anticoagulation and consider whether benefit of transfusion reduction outweighs increased risk of post-operative thrombotic/vascular events.
Increased mortality, serious cardiovascular events, and thromboembolic events when hemoglobin exceeds 11 g/d L; increased risk of tumor progression or recurrence in cancer patients; increased risk of seizures; pure red cell aplasia (PRCA) due to neutralizing antibodies; severe allergic reactions including anaphylaxis; hypertension; use with caution in patients with uncontrolled hypertension, history of seizures, or known hypersensitivity to albumin (human) or mammalian cell-derived products.
Increased mortality, myocardial infarction, stroke, and thromboembolism,Increased risk of thrombosis of vascular access,Increased mortality and/or tumor progression in cancer patients,Hypertension,Seizures,Pure red cell aplasia (PRCA) due to anti-erythropoietin antibodies,Serious allergic reactions,Possible worsening of anemia due to antibody-mediated PRCA,Risk of cardiovascular events when hemoglobin exceeds 11 g/d L,Need for iron supplementation,Monitoring of hemoglobin and blood pressure
Uncontrolled hypertension; known hypersensitivity to the drug or its components (including albumin human or mammalian cell-derived products); history of pure red cell aplasia (PRCA) following epoetin alfa therapy; use in patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure.
Uncontrolled hypertension,Pure red cell aplasia (PRCA) that begins after treatment with epoetin alfa or other ESAs,Known hypersensitivity to epoetin alfa-epbx or any component of the product
No specific food restrictions. Maintain adequate dietary iron intake (e.g., red meat, leafy greens) to support erythropoiesis. Avoid excessive alcohol which may interfere with treatment efficacy.
No specific food interactions. Maintain adequate iron intake; consider dietary sources of iron (e.g., red meat, leafy greens) if not on supplements. No restrictions with alcohol or other foods.
Pregnancy Category C. Animal studies have shown adverse effects (increased fetal mortality, growth retardation) at doses 2-3 times the human dose. No adequate well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to fetus. First trimester: limited data, risk cannot be excluded. Second and third trimesters: may increase risk of hypertensive episodes and thrombotic events, which can compromise placental perfusion.
Retacrit (epoetin alfa-epbx) is a recombinant human erythropoietin. In animal studies, epoetin alfa did not demonstrate teratogenicity at clinically relevant doses. However, there are no adequate and well-controlled studies in pregnant women. Potential fetal risks include hypertension and thromboembolic events secondary to maternal polycythemia. Use during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus.
Recombinant erythropoietin is excreted in human milk in very low amounts; however, absorption from infant gastrointestinal tract is limited. The M/P ratio is unknown. Consider benefits of breastfeeding, mother's need for drug, and potential adverse effects on infant (e.g., polycythemia, hypertension). Caution advised.
It is not known whether epoetin alfa is excreted in human milk. Endogenous erythropoietin is present in breast milk. M/P ratio not available. Caution should be exercised when Retacrit is administered to a nursing woman. Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug and any potential adverse effects on the breastfed child from the drug or underlying maternal condition.
There are no established dosing adjustments specific to pregnancy. Pharmacokinetic studies in pregnant women are lacking; however, physiologic changes (increased plasma volume, increased clearance) may require dose increases to maintain target hemoglobin levels. Individualize dosing to achieve hemoglobin levels within recommended range (10-12 g/d L) to avoid risks associated with high hemoglobin (hypertension, thrombosis) and low hemoglobin (poor fetal outcomes).
No specific dose adjustments for Retacrit are recommended during pregnancy based on pharmacokinetic changes. However, pregnant women may have increased plasma volume and altered erythropoietin kinetics. The lowest effective dose to gradually increase hemoglobin to the target level (not to exceed 12 g/d L in chronic kidney disease) should be used. Close monitoring of hemoglobin and blood pressure is essential to avoid excessive erythrocytosis and associated risks.
Monitor hemoglobin weekly during initiation and dose titration; target Hb 10-12 g/d L to avoid cardiovascular events. Do not shake vial; use one dose per vial (preservative-free). Administer IV or SC; SC preferred for CKD patients. Iron deficiency must be corrected to ensure response; check ferritin and transferrin saturation. Hypertension is common; monitor BP. Hold dose if Hb > 13 g/d L or rapid rise > 1 g/d L in 2 weeks. Risk of pure red cell aplasia with SC use in CKD; switch to IV if suspected. Store refrigerated, do not freeze; protect from light. In cancer patients, use only for chemotherapy-induced anemia; not for patients receiving curative therapy.
Retacrit (epoetin alfa-epbx) is a biosimilar to Epogen/Procrit. Monitor hemoglobin weekly until stable, then monthly; target Hb 10-12 g/d L. Do not use to replace urgent transfusions. Iron stores must be adequate; check ferritin and transferrin saturation. Increased risk of thrombotic events, especially in patients with cardiovascular disease. Do not shake vial; use one vial per dose; discard unused portion. Administer subcutaneously or intravenously; rotate injection sites.
This medicine helps your body make more red blood cells to treat anemia.,You will have regular blood tests to check your hemoglobin level and adjust the dose.,Report any symptoms of high blood pressure, such as severe headache, chest pain, or shortness of breath.,Do not miss any appointments for injections; keep a calendar or set reminders.,Store the medication in the refrigerator at 36°F to 46°F; do not freeze or shake.,Take iron supplements exactly as prescribed; iron is needed for this medicine to work.,Tell your doctor if you experience sudden anemia, loss of response, or severe tiredness.
This medication helps your body make more red blood cells to treat anemia.,You will have regular blood tests to check your hemoglobin levels and iron stores.,Do not miss scheduled appointments for monitoring; call your doctor if you have symptoms of a blood clot (chest pain, sudden shortness of breath, leg swelling).,It is important to take iron supplements as prescribed while on this medication.,Store Retacrit in the refrigerator; do not freeze or shake the vial.,Report any signs of allergic reaction (rash, itching, swelling).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EPOGEN/PROCRIT vs RETACRIT, answered by our medical review team.
EPOGEN/PROCRIT is a Erythropoiesis-Stimulating Agent that works by Erythropoiesis-stimulating agent that binds to and activates the erythropoietin receptor on erythroid progenitor cells, stimulating proliferation and differentiation into mature red blood cells.. RETACRIT is a Erythropoiesis-Stimulating Agent that works by RETACRIT (epoetin alfa-epbx) is a recombinant human erythropoietin that stimulates erythropoiesis by binding to and activating the erythropoietin receptor on erythroid progenitor cells, promoting their survival, proliferation, and differentiation into mature red blood cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EPOGEN/PROCRIT and RETACRIT depend on the specific clinical indication. These are both Erythropoiesis-Stimulating Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EPOGEN/PROCRIT is: 50-100 units/kg intravenously or subcutaneously three times weekly. Initial dose 50 units/kg three times weekly; adjust to maintain hemoglobin target (usually 10-12 g/d L).. The standard adult dose of RETACRIT is: 50-100 IU/kg intravenously or subcutaneously three times weekly; initial dose 50 IU/kg three times weekly, titrated to target hemoglobin 10-12 g/d L.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EPOGEN/PROCRIT and RETACRIT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EPOGEN/PROCRIT is classified as Category C. Pregnancy Category C. Animal studies have shown adverse effects (increased fetal mortality, growth retardation) at doses 2-3 times the human dose. No adequate well-controlled studi. RETACRIT is classified as Category C. Retacrit (epoetin alfa-epbx) is a recombinant human erythropoietin. In animal studies, epoetin alfa did not demonstrate teratogenicity at clinically relevant doses. However, there . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.